View Future GrowthChina SXT Pharmaceuticals 과거 순이익 실적과거 기준 점검 0/6China SXT Pharmaceuticals은 연평균 8.6%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 9.7%의 비율로 증가했습니다. 매출은 연평균 24.8%의 비율로 감소했습니다.핵심 정보8.57%순이익 성장률n/a주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률-24.79%자기자본이익률-43.84%순이익률-576.72%최근 순이익 업데이트30 Sep 2025최근 과거 실적 업데이트Reported Earnings • Jan 02First half 2026 earnings released: US$0.055 loss per share (vs US$0.25 loss in 1H 2025)First half 2026 results: US$0.055 loss per share. Net loss: US$6.37m (loss widened US$5.57m from 1H 2025).Reported Earnings • Aug 01Full year 2025 earnings released: US$2.32 loss per share (vs US$28.58 loss in FY 2024)Full year 2025 results: US$2.32 loss per share. Revenue: US$1.74m (down 9.7% from FY 2024). Net loss: US$3.30m (loss widened 6.6% from FY 2024).Reported Earnings • Apr 03First half 2025 earnings released: US$1.99 loss per share (vs US$155 loss in 1H 2024)First half 2025 results: US$1.99 loss per share (improved from US$155 loss in 1H 2024). Net loss: US$802.6k (loss narrowed 92% from 1H 2024).Reported Earnings • Aug 01Full year 2023 earnings released: US$0.89 loss per share (vs US$5.52 loss in FY 2022)Full year 2023 results: US$0.89 loss per share. Net loss: US$5.93m (loss widened 3.5% from FY 2022).Reported Earnings • Feb 26First half 2023 earnings released: US$0.58 loss per share (vs US$3.98 loss in 1H 2022)First half 2023 results: US$0.58 loss per share (improved from US$3.98 loss in 1H 2022). Revenue: US$1.21m (up 18% from 1H 2022). Net loss: US$1.49m (loss narrowed 52% from 1H 2022).Reported Earnings • Jul 19Full year 2022 earnings released: US$5.52 loss per share (vs US$3.82 loss in FY 2021)Full year 2022 results: US$5.52 loss per share (down from US$3.82 loss in FY 2021). Revenue: US$2.60m (down 46% from FY 2021). Net loss: US$5.74m (loss widened 109% from FY 2021).모든 업데이트 보기Recent updates공시 • Apr 09China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.76 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.76 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 2,000,000 Price\Range: $0.38 Transaction Features: Registered Direct Offering공시 • Jan 14China SXT Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $9.945333 million.China SXT Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $9.945333 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 12,000,000 Price\Range: $0.15 Discount Per Security: $0.0105 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 54,666,666 Price\Range: $0.149 Discount Per Security: $0.01043 Transaction Features: Registered Direct OfferingNew Risk • Jan 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$17.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (over 266x increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$1.5m revenue). Market cap is less than US$100m (US$17.5m market cap).공시 • Jan 10China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 66,666,666 Price\Range: $0.15 Transaction Features: Registered Direct OfferingNew Risk • Jan 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (over 266x increase in shares outstanding). Minor Risk Revenue is less than US$5m (US$1.5m revenue).Reported Earnings • Jan 02First half 2026 earnings released: US$0.055 loss per share (vs US$0.25 loss in 1H 2025)First half 2026 results: US$0.055 loss per share. Net loss: US$6.37m (loss widened US$5.57m from 1H 2025).Reported Earnings • Aug 01Full year 2025 earnings released: US$2.32 loss per share (vs US$28.58 loss in FY 2024)Full year 2025 results: US$2.32 loss per share. Revenue: US$1.74m (down 9.7% from FY 2024). Net loss: US$3.30m (loss widened 6.6% from FY 2024).Valuation Update With 7 Day Price Move • May 23Investor sentiment improves as stock rises 29%After last week's 29% share price gain to US$1.55, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years.Valuation Update With 7 Day Price Move • May 07Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to US$1.90, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years.공시 • May 07China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.1 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 200,000 Price\Range: $0.5 Transaction Features: Registered Direct OfferingValuation Update With 7 Day Price Move • Apr 15Investor sentiment deteriorates as stock falls 32%After last week's 32% share price decline to US$1.70, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 15x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years.Reported Earnings • Apr 03First half 2025 earnings released: US$1.99 loss per share (vs US$155 loss in 1H 2024)First half 2025 results: US$1.99 loss per share (improved from US$155 loss in 1H 2024). Net loss: US$802.6k (loss narrowed 92% from 1H 2024).New Risk • Apr 02New major risk - Revenue and earnings growthRevenue has declined by 2.2% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Revenue has declined by 2.2% over the past year. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$1.12m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Revenue is less than US$5m (US$1.9m revenue).공시 • Mar 18China SXT Pharmaceuticals Regains Compliance with Nasdaq's Minimum Bid Price DeficiencyChina SXT Pharmaceuticals, Inc. announced that the Company received a written notification (the “Compliance Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”) and the matter is closed. As previously announced, the Company received a notification letter from the Nasdaq dated October 3, 2024, indicating its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days under Minimum Bid Price Requirement. Pursuant to the Nasdaq Listing Rules 5810(c)(3)(A), the Company was provided with 180 calendar days, or until April 1, 2025, to regain compliance. To comply with the Minimum Bid Price Requirement, the closing bid price of the Company’s ordinary shares must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to April 1, 2025. Therefore, in order to cure the Minimum Bid Price deficiency, the Company has effectuated a share consolidation on February 25, 2025, of which every eight (8) issued and unissued ordinary shares of the Company with no par value each be consolidated into one (1) share with no par value. According to the Compliance Notice, the Company evidenced a closing bid price of its ordinary shares at or greater than $1.00 per share for 10 consecutive business days from February 25, 2025 to March 12, 2025. Thus, the Company has regained compliance with the Minimum Bid Price Requirement, and the matter is closed.New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$1.96m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Revenue is less than US$5m (US$1.9m revenue).New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 45% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (45% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$1.19m market cap). Minor Risk Revenue is less than US$5m (US$1.9m revenue).공시 • Feb 22China SXT Pharmaceuticals, Inc. Announces Share Consolidation to Regain Compliance with the Minimum Bid Price RequirementChina SXT Pharmaceutics, Inc. announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-8, effective on February 25, 2025 (the “Share Consolidation”). The Company’s ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on February 25, 2025. Upon the market opening on February 25, 2025, the Company’s ordinary shares will continue to be traded on The Nasdaq Stock Market under the symbol “SXTC” with the new CUSIP number G2161P157. The Company’s Board of Directors approved the afore-mentioned Share Consolidation so as to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market (the “Minimum Bid Price Requirement”). In order to maintain the Company’s listing on the Nasdaq Stock Market, the Company’s ordinary shares must have a closing bid price of $1.00 or more for a minimum of ten consecutive trading days by April 1, 2025. There can be no assurance that following the Share Consolidation, the Company’s ordinary shares will remain above $1.00 per share minimum for the requisite period to regain listing compliance. In the event that the Company does not regain compliance with the Minimum Bid Price Requirement, its securities may be subject to delisting from the Nasdaq Stock Market which, in turn, will result in significant adverse effect on the value and liquidity of the Company’s securities.공시 • Jan 25China SXT Pharmaceuticals, Inc. Announces CEO ChangesOn January 20, 2025, the Board of China SXT Pharmaceuticals, Inc. approved the appointment of Mr. Simon Lim Sze Beng as the Co-Chief Executive Officer (the "Co-CEO") of the Company with immediate effect. In connection with this appointment, the title of Mr. Feng Zhou was changed from the Chief Executive Officer and Director to the Co-CEO and Director of the Company. Mr. Simon Lim Sze Beng is an experienced professional in the healthcare sector. Since 2019, he has served as a manager of Reform Medical Marketing Co., Limited, where he serves clients in medical, and healthcare sectors and promotes their products and services. From 2017 to 2019, he was the senior operations director at Axcel Digital, where he conducts multichannel promotion for healthcare sector clients. He earned a bachelor's degree in arts from Universiti Malaya in Malaysia in 2001.공시 • Jan 24China SXT Pharmaceuticals, Inc. Announces Board and Committee ChangesOn January 20, 2025, Songfan He resigned from his positions as an independent director of the board of directors of China SXT Pharmaceuticals, Inc., the chairman of the audit committee, a member of the compensation committee and nominating & corporate governance committee, effective immediately. Mr. He indicated that his resignation was due to personal reasons and was not the result of any disagreement with management of the Company or the Board. On January 20, 2025, the Board of the Company passed a resolution to appoint Mr. Yong Lip Chee as an independent director of the Board, the chairman of the Audit Committee, a member of the Compensation Committee and the Nominating Committee, to fill in the vacancies result from Mr. He's resignation. Mr. Yong Lip Chee has a background in sales and client relations within the healthcare sector. Since 2021, Mr. Yong has been an independent sales consultant, advising healthcare companies on market penetration strategies and distributor partnerships. From 2017 to 2021, he served as a sales supervisor at Winner Medical Hong Kong, where he promotes medical consumables products to hospitals and private healthcare medical professionals and related users. He earned a bachelor's degree in business administration from Universiti Malaya in Malaysia in 2013.공시 • Oct 08China SXT Pharmaceuticals Receives Nasdaq Notification Letter Regarding Bid Price DeficiencyChina SXT Pharmaceuticals, Inc. announced that on October 3, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC (“Nasdaq”) notifying the Company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s ordinary shares on Nasdaq. Under the Nasdaq Listing Rules, the Company has until April 1, 2025, to regain compliance. If at any time during such 180-day period the closing bid price of the Company’s ordinary shares is at least $1 for a minimum of 10 consecutive business days, Nasdaq will provide the Company written confirmation of compliance. If the Company does not regain compliance during such 180-day period, the Company may be eligible for an additional 180 calendar days, provided that the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq except for Nasdaq Listing Rule 5550(a)(2), and provide a written notice of its intention to cure this deficiency during the second compliance period, by effecting a reverse stock split, if necessary.공시 • Aug 01China SXT Pharmaceuticals, Inc. announced delayed 20-F filingOn 07/31/2024, China SXT Pharmaceuticals, Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.New Risk • Apr 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 74% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 33% per year over the past 5 years. Shareholders have been substantially diluted in the past year (74% increase in shares outstanding). Market cap is less than US$10m (US$1.08m market cap). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (US$1.7m revenue).New Risk • Feb 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (34% average weekly change). Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Market cap is less than US$10m (US$1.23m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Revenue is less than US$5m (US$2.0m revenue).공시 • Oct 27China SXT Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price RuleChina SXT Pharmaceuticals, Inc. announced that on October 19, 2023, NASDAQ notified us that it has determined that for the 10 consecutive business days, from October 5, 2023 to October 13, 2023, the closing bid price of the Company’s ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and NASDAQ has closed this matter.공시 • Oct 05China SXT Pharmaceuticals Announces One-for-Twenty-Five Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Stock MarketChina SXT Pharmaceuticals, Inc. (the ‘company’) announced that its Board of Directors has set the date of October 5, 2023 to be the effective date for the Company’s one-for-twenty-five reverse stock split of its issued and outstanding ordinary shares. The Company’s ordinary shares will begin trading on the NASDAQ Stock Market on a split-adjusted basis when the market opens on October 5, 2023. The CUSIP number for the Company’s ordinary shares will be changed to G2161P140. The Company’s Board of Directors approved a reverse stock split so as to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Stock Market. In order to maintain the Company’s listing on the NASDAQ Capital Market, the Company’s ordinary shares must have a closing bid price of $1.00 or more for a minimum of ten consecutive trading days by October 30, 2023. There can be no assurance that following the reverse split, the Company’s ordinary shares will remain above $1.00 per share minimum for the requisite period as of October 30, 2023 to regain listing compliance. In the event the Company does not regain compliance with the minimum bid price requirement, its securities may be subject to delisting from the NASDAQ Stock Market which, in turn, will result in significant adverse effect on the value and liquidity of the Company’s securities.Reported Earnings • Aug 01Full year 2023 earnings released: US$0.89 loss per share (vs US$5.52 loss in FY 2022)Full year 2023 results: US$0.89 loss per share. Net loss: US$5.93m (loss widened 3.5% from FY 2022).공시 • May 11China SXT Pharmaceuticals Receives 180-Day Extension from Nasdaq to Meet Minimum Bid Price RuleOn May 10, 2023, China SXT Pharmaceuticals, Inc. announced that on May 4, 2023, the company received a written notification from the Nasdaq's Listing Qualifications Department, granting the company another 180 calendar days extension, or until October 30, 2023, to regain compliance with Nasdaq’s minimum bid price requirement. The company can cure this deficiency if the closing bid price of its ordinary shares is $1.00 per share or higher for at least 10 consecutive business days during this second compliance period. The Company intends to regain compliance with the minimum bid price requirement on or before October 30, 2023 and is considering all available options, including a reverse stock split if necessary. During this time, the Company's ordinary shares will continue to be listed and traded on the Nasdaq Capital Market, and this notice will have no effect on the operations of the Company’s business.Reported Earnings • Feb 26First half 2023 earnings released: US$0.58 loss per share (vs US$3.98 loss in 1H 2022)First half 2023 results: US$0.58 loss per share (improved from US$3.98 loss in 1H 2022). Revenue: US$1.21m (up 18% from 1H 2022). Net loss: US$1.49m (loss narrowed 52% from 1H 2022).Reported Earnings • Jul 19Full year 2022 earnings released: US$5.52 loss per share (vs US$3.82 loss in FY 2021)Full year 2022 results: US$5.52 loss per share (down from US$3.82 loss in FY 2021). Revenue: US$2.60m (down 46% from FY 2021). Net loss: US$5.74m (loss widened 109% from FY 2021).Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Wenwei Fan was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Jan 19First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: US$0.20 loss per share (down from US$0.096 profit in 1H 2021). Revenue: US$1.03m (down 73% from 1H 2021). Net loss: US$3.09m (down 324% from profit in 1H 2021). Revenue was in line with analyst estimates.Board Change • Nov 02Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Junsong Li is the most experienced director on the board, commencing their role in 2019. Independent Director Wenwei Fan was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Is New 90 Day High Low • Feb 17New 90-day high: US$1.28The company is up 360% from its price of US$0.28 on 18 November 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 15% over the same period.분석 기사 • Feb 09China SXT Pharmaceuticals'(NASDAQ:SXTC) Share Price Is Down 12% Over The Past Year.It is doubtless a positive to see that the China SXT Pharmaceuticals, Inc. ( NASDAQ:SXTC ) share price has gained some...Reported Earnings • Jan 31First half 2021 earnings released: EPS US$0.026 (vs US$0.10 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: US$3.86m (up 20% from 1H 2020). Net income: US$1.38m (up US$3.73m from 1H 2020). Profit margin: 36% (up from net loss in 1H 2020).Is New 90 Day High Low • Jan 30New 90-day high: US$0.73The company is up 157% from its price of US$0.28 on 30 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 17% over the same period.Is New 90 Day High Low • Jan 05New 90-day high: US$0.39The company is up 56% from its price of US$0.25 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 22% over the same period.Is New 90 Day High Low • Dec 02New 90-day high: US$0.34The company is up 28% from its price of US$0.27 on 02 September 2020. The American market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 14% over the same period.Is New 90 Day High Low • Sep 22New 90-day low: US$0.23The company is down 52% from its price of US$0.48 on 24 June 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 8.0% over the same period.매출 및 비용 세부 내역China SXT Pharmaceuticals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:SXTC 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 252-99030 Jun 252-66031 Mar 252-33031 Dec 2421-2030 Sep 2426-6030 Jun 2421-2031 Mar 242-33031 Dec 232-98030 Sep 232-1414030 Jun 232-1010031 Mar 232-66031 Dec 222-55030 Sep 223-44030 Jun 223-55031 Mar 223-66031 Dec 212-67030 Sep 212-77030 Jun 213-56031 Mar 215-35031 Dec 205-54030 Sep 206-74030 Jun 205-84031 Mar 205-104031 Dec 196-64030 Sep 196-24030 Jun 19703031 Mar 19723031 Dec 18713030 Sep 18713030 Jun 18712031 Mar 18712031 Dec 17711031 Mar 17511031 Mar 164010양질의 수익: SXTC 은(는) 현재 수익성이 없습니다.이익 마진 증가: SXTC는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: SXTC는 수익성이 없지만 지난 5년 동안 연평균 8.6%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 SXTC의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: SXTC은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: SXTC는 현재 수익성이 없으므로 자본 수익률이 음수(-43.84%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 10:25종가2026/05/22 00:00수익2025/09/30연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스China SXT Pharmaceuticals, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Jan 02First half 2026 earnings released: US$0.055 loss per share (vs US$0.25 loss in 1H 2025)First half 2026 results: US$0.055 loss per share. Net loss: US$6.37m (loss widened US$5.57m from 1H 2025).
Reported Earnings • Aug 01Full year 2025 earnings released: US$2.32 loss per share (vs US$28.58 loss in FY 2024)Full year 2025 results: US$2.32 loss per share. Revenue: US$1.74m (down 9.7% from FY 2024). Net loss: US$3.30m (loss widened 6.6% from FY 2024).
Reported Earnings • Apr 03First half 2025 earnings released: US$1.99 loss per share (vs US$155 loss in 1H 2024)First half 2025 results: US$1.99 loss per share (improved from US$155 loss in 1H 2024). Net loss: US$802.6k (loss narrowed 92% from 1H 2024).
Reported Earnings • Aug 01Full year 2023 earnings released: US$0.89 loss per share (vs US$5.52 loss in FY 2022)Full year 2023 results: US$0.89 loss per share. Net loss: US$5.93m (loss widened 3.5% from FY 2022).
Reported Earnings • Feb 26First half 2023 earnings released: US$0.58 loss per share (vs US$3.98 loss in 1H 2022)First half 2023 results: US$0.58 loss per share (improved from US$3.98 loss in 1H 2022). Revenue: US$1.21m (up 18% from 1H 2022). Net loss: US$1.49m (loss narrowed 52% from 1H 2022).
Reported Earnings • Jul 19Full year 2022 earnings released: US$5.52 loss per share (vs US$3.82 loss in FY 2021)Full year 2022 results: US$5.52 loss per share (down from US$3.82 loss in FY 2021). Revenue: US$2.60m (down 46% from FY 2021). Net loss: US$5.74m (loss widened 109% from FY 2021).
공시 • Apr 09China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.76 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.76 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 2,000,000 Price\Range: $0.38 Transaction Features: Registered Direct Offering
공시 • Jan 14China SXT Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $9.945333 million.China SXT Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $9.945333 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 12,000,000 Price\Range: $0.15 Discount Per Security: $0.0105 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 54,666,666 Price\Range: $0.149 Discount Per Security: $0.01043 Transaction Features: Registered Direct Offering
New Risk • Jan 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$17.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (over 266x increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$1.5m revenue). Market cap is less than US$100m (US$17.5m market cap).
공시 • Jan 10China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 66,666,666 Price\Range: $0.15 Transaction Features: Registered Direct Offering
New Risk • Jan 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (over 266x increase in shares outstanding). Minor Risk Revenue is less than US$5m (US$1.5m revenue).
Reported Earnings • Jan 02First half 2026 earnings released: US$0.055 loss per share (vs US$0.25 loss in 1H 2025)First half 2026 results: US$0.055 loss per share. Net loss: US$6.37m (loss widened US$5.57m from 1H 2025).
Reported Earnings • Aug 01Full year 2025 earnings released: US$2.32 loss per share (vs US$28.58 loss in FY 2024)Full year 2025 results: US$2.32 loss per share. Revenue: US$1.74m (down 9.7% from FY 2024). Net loss: US$3.30m (loss widened 6.6% from FY 2024).
Valuation Update With 7 Day Price Move • May 23Investor sentiment improves as stock rises 29%After last week's 29% share price gain to US$1.55, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years.
Valuation Update With 7 Day Price Move • May 07Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to US$1.90, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years.
공시 • May 07China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.1 million.China SXT Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 200,000 Price\Range: $0.5 Transaction Features: Registered Direct Offering
Valuation Update With 7 Day Price Move • Apr 15Investor sentiment deteriorates as stock falls 32%After last week's 32% share price decline to US$1.70, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 15x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years.
Reported Earnings • Apr 03First half 2025 earnings released: US$1.99 loss per share (vs US$155 loss in 1H 2024)First half 2025 results: US$1.99 loss per share (improved from US$155 loss in 1H 2024). Net loss: US$802.6k (loss narrowed 92% from 1H 2024).
New Risk • Apr 02New major risk - Revenue and earnings growthRevenue has declined by 2.2% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Revenue has declined by 2.2% over the past year. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$1.12m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Revenue is less than US$5m (US$1.9m revenue).
공시 • Mar 18China SXT Pharmaceuticals Regains Compliance with Nasdaq's Minimum Bid Price DeficiencyChina SXT Pharmaceuticals, Inc. announced that the Company received a written notification (the “Compliance Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”) and the matter is closed. As previously announced, the Company received a notification letter from the Nasdaq dated October 3, 2024, indicating its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days under Minimum Bid Price Requirement. Pursuant to the Nasdaq Listing Rules 5810(c)(3)(A), the Company was provided with 180 calendar days, or until April 1, 2025, to regain compliance. To comply with the Minimum Bid Price Requirement, the closing bid price of the Company’s ordinary shares must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to April 1, 2025. Therefore, in order to cure the Minimum Bid Price deficiency, the Company has effectuated a share consolidation on February 25, 2025, of which every eight (8) issued and unissued ordinary shares of the Company with no par value each be consolidated into one (1) share with no par value. According to the Compliance Notice, the Company evidenced a closing bid price of its ordinary shares at or greater than $1.00 per share for 10 consecutive business days from February 25, 2025 to March 12, 2025. Thus, the Company has regained compliance with the Minimum Bid Price Requirement, and the matter is closed.
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$1.96m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Revenue is less than US$5m (US$1.9m revenue).
New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 45% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (45% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$1.19m market cap). Minor Risk Revenue is less than US$5m (US$1.9m revenue).
공시 • Feb 22China SXT Pharmaceuticals, Inc. Announces Share Consolidation to Regain Compliance with the Minimum Bid Price RequirementChina SXT Pharmaceutics, Inc. announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-8, effective on February 25, 2025 (the “Share Consolidation”). The Company’s ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on February 25, 2025. Upon the market opening on February 25, 2025, the Company’s ordinary shares will continue to be traded on The Nasdaq Stock Market under the symbol “SXTC” with the new CUSIP number G2161P157. The Company’s Board of Directors approved the afore-mentioned Share Consolidation so as to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market (the “Minimum Bid Price Requirement”). In order to maintain the Company’s listing on the Nasdaq Stock Market, the Company’s ordinary shares must have a closing bid price of $1.00 or more for a minimum of ten consecutive trading days by April 1, 2025. There can be no assurance that following the Share Consolidation, the Company’s ordinary shares will remain above $1.00 per share minimum for the requisite period to regain listing compliance. In the event that the Company does not regain compliance with the Minimum Bid Price Requirement, its securities may be subject to delisting from the Nasdaq Stock Market which, in turn, will result in significant adverse effect on the value and liquidity of the Company’s securities.
공시 • Jan 25China SXT Pharmaceuticals, Inc. Announces CEO ChangesOn January 20, 2025, the Board of China SXT Pharmaceuticals, Inc. approved the appointment of Mr. Simon Lim Sze Beng as the Co-Chief Executive Officer (the "Co-CEO") of the Company with immediate effect. In connection with this appointment, the title of Mr. Feng Zhou was changed from the Chief Executive Officer and Director to the Co-CEO and Director of the Company. Mr. Simon Lim Sze Beng is an experienced professional in the healthcare sector. Since 2019, he has served as a manager of Reform Medical Marketing Co., Limited, where he serves clients in medical, and healthcare sectors and promotes their products and services. From 2017 to 2019, he was the senior operations director at Axcel Digital, where he conducts multichannel promotion for healthcare sector clients. He earned a bachelor's degree in arts from Universiti Malaya in Malaysia in 2001.
공시 • Jan 24China SXT Pharmaceuticals, Inc. Announces Board and Committee ChangesOn January 20, 2025, Songfan He resigned from his positions as an independent director of the board of directors of China SXT Pharmaceuticals, Inc., the chairman of the audit committee, a member of the compensation committee and nominating & corporate governance committee, effective immediately. Mr. He indicated that his resignation was due to personal reasons and was not the result of any disagreement with management of the Company or the Board. On January 20, 2025, the Board of the Company passed a resolution to appoint Mr. Yong Lip Chee as an independent director of the Board, the chairman of the Audit Committee, a member of the Compensation Committee and the Nominating Committee, to fill in the vacancies result from Mr. He's resignation. Mr. Yong Lip Chee has a background in sales and client relations within the healthcare sector. Since 2021, Mr. Yong has been an independent sales consultant, advising healthcare companies on market penetration strategies and distributor partnerships. From 2017 to 2021, he served as a sales supervisor at Winner Medical Hong Kong, where he promotes medical consumables products to hospitals and private healthcare medical professionals and related users. He earned a bachelor's degree in business administration from Universiti Malaya in Malaysia in 2013.
공시 • Oct 08China SXT Pharmaceuticals Receives Nasdaq Notification Letter Regarding Bid Price DeficiencyChina SXT Pharmaceuticals, Inc. announced that on October 3, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC (“Nasdaq”) notifying the Company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s ordinary shares on Nasdaq. Under the Nasdaq Listing Rules, the Company has until April 1, 2025, to regain compliance. If at any time during such 180-day period the closing bid price of the Company’s ordinary shares is at least $1 for a minimum of 10 consecutive business days, Nasdaq will provide the Company written confirmation of compliance. If the Company does not regain compliance during such 180-day period, the Company may be eligible for an additional 180 calendar days, provided that the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq except for Nasdaq Listing Rule 5550(a)(2), and provide a written notice of its intention to cure this deficiency during the second compliance period, by effecting a reverse stock split, if necessary.
공시 • Aug 01China SXT Pharmaceuticals, Inc. announced delayed 20-F filingOn 07/31/2024, China SXT Pharmaceuticals, Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
New Risk • Apr 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 74% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 33% per year over the past 5 years. Shareholders have been substantially diluted in the past year (74% increase in shares outstanding). Market cap is less than US$10m (US$1.08m market cap). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (US$1.7m revenue).
New Risk • Feb 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (34% average weekly change). Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Market cap is less than US$10m (US$1.23m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Revenue is less than US$5m (US$2.0m revenue).
공시 • Oct 27China SXT Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price RuleChina SXT Pharmaceuticals, Inc. announced that on October 19, 2023, NASDAQ notified us that it has determined that for the 10 consecutive business days, from October 5, 2023 to October 13, 2023, the closing bid price of the Company’s ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and NASDAQ has closed this matter.
공시 • Oct 05China SXT Pharmaceuticals Announces One-for-Twenty-Five Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Stock MarketChina SXT Pharmaceuticals, Inc. (the ‘company’) announced that its Board of Directors has set the date of October 5, 2023 to be the effective date for the Company’s one-for-twenty-five reverse stock split of its issued and outstanding ordinary shares. The Company’s ordinary shares will begin trading on the NASDAQ Stock Market on a split-adjusted basis when the market opens on October 5, 2023. The CUSIP number for the Company’s ordinary shares will be changed to G2161P140. The Company’s Board of Directors approved a reverse stock split so as to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Stock Market. In order to maintain the Company’s listing on the NASDAQ Capital Market, the Company’s ordinary shares must have a closing bid price of $1.00 or more for a minimum of ten consecutive trading days by October 30, 2023. There can be no assurance that following the reverse split, the Company’s ordinary shares will remain above $1.00 per share minimum for the requisite period as of October 30, 2023 to regain listing compliance. In the event the Company does not regain compliance with the minimum bid price requirement, its securities may be subject to delisting from the NASDAQ Stock Market which, in turn, will result in significant adverse effect on the value and liquidity of the Company’s securities.
Reported Earnings • Aug 01Full year 2023 earnings released: US$0.89 loss per share (vs US$5.52 loss in FY 2022)Full year 2023 results: US$0.89 loss per share. Net loss: US$5.93m (loss widened 3.5% from FY 2022).
공시 • May 11China SXT Pharmaceuticals Receives 180-Day Extension from Nasdaq to Meet Minimum Bid Price RuleOn May 10, 2023, China SXT Pharmaceuticals, Inc. announced that on May 4, 2023, the company received a written notification from the Nasdaq's Listing Qualifications Department, granting the company another 180 calendar days extension, or until October 30, 2023, to regain compliance with Nasdaq’s minimum bid price requirement. The company can cure this deficiency if the closing bid price of its ordinary shares is $1.00 per share or higher for at least 10 consecutive business days during this second compliance period. The Company intends to regain compliance with the minimum bid price requirement on or before October 30, 2023 and is considering all available options, including a reverse stock split if necessary. During this time, the Company's ordinary shares will continue to be listed and traded on the Nasdaq Capital Market, and this notice will have no effect on the operations of the Company’s business.
Reported Earnings • Feb 26First half 2023 earnings released: US$0.58 loss per share (vs US$3.98 loss in 1H 2022)First half 2023 results: US$0.58 loss per share (improved from US$3.98 loss in 1H 2022). Revenue: US$1.21m (up 18% from 1H 2022). Net loss: US$1.49m (loss narrowed 52% from 1H 2022).
Reported Earnings • Jul 19Full year 2022 earnings released: US$5.52 loss per share (vs US$3.82 loss in FY 2021)Full year 2022 results: US$5.52 loss per share (down from US$3.82 loss in FY 2021). Revenue: US$2.60m (down 46% from FY 2021). Net loss: US$5.74m (loss widened 109% from FY 2021).
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Wenwei Fan was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jan 19First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: US$0.20 loss per share (down from US$0.096 profit in 1H 2021). Revenue: US$1.03m (down 73% from 1H 2021). Net loss: US$3.09m (down 324% from profit in 1H 2021). Revenue was in line with analyst estimates.
Board Change • Nov 02Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Junsong Li is the most experienced director on the board, commencing their role in 2019. Independent Director Wenwei Fan was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Is New 90 Day High Low • Feb 17New 90-day high: US$1.28The company is up 360% from its price of US$0.28 on 18 November 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 15% over the same period.
분석 기사 • Feb 09China SXT Pharmaceuticals'(NASDAQ:SXTC) Share Price Is Down 12% Over The Past Year.It is doubtless a positive to see that the China SXT Pharmaceuticals, Inc. ( NASDAQ:SXTC ) share price has gained some...
Reported Earnings • Jan 31First half 2021 earnings released: EPS US$0.026 (vs US$0.10 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: US$3.86m (up 20% from 1H 2020). Net income: US$1.38m (up US$3.73m from 1H 2020). Profit margin: 36% (up from net loss in 1H 2020).
Is New 90 Day High Low • Jan 30New 90-day high: US$0.73The company is up 157% from its price of US$0.28 on 30 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 17% over the same period.
Is New 90 Day High Low • Jan 05New 90-day high: US$0.39The company is up 56% from its price of US$0.25 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 22% over the same period.
Is New 90 Day High Low • Dec 02New 90-day high: US$0.34The company is up 28% from its price of US$0.27 on 02 September 2020. The American market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 14% over the same period.
Is New 90 Day High Low • Sep 22New 90-day low: US$0.23The company is down 52% from its price of US$0.48 on 24 June 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 8.0% over the same period.